Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B001 in AQP4-IgG Positive NMOSD
NCT05145361Phase 1Recruiting
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Apr 2022
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Neuromyelitis Optica Spectrum Disorder (NMOSD) comparing B001 injection with Placebo (2 arms). Primary endpoints: Dose-Limiting Toxicity at 18 days and Treatment-Emergent Adverse Events at 1 year. Started Apr 2022; status: recruiting.
02
Drugs
B001
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05145361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05145361.